Research

For over 30 years, Dr. Dale Bredesen and others around the globe have been pursuing effective treatments for Alzheimer's disease.  His ReCODE (Reversing COgnitive DEcline) Protocol is a culmination of these therapies and produces unprecedented results in halting and reversing disease progression.  Below are the most pertinent research articles.

The most recent peer-reviewed published report in a scientific journal of 34 patients treated with a highly personalized approach (similar to Dr. Eads' program) over 6 months.  These patients, with Objective Cognitive Impairment, received targeted treatments based on their testing and achieved statistically significant improvement in multiple parameters of cognition. This  study demonstrates the feasibility and impact of a multimodal intervention approach to cognitive impairment. Link to article here.

A peer-reviewed published report in a scientific journal of 25 patients treated with a highly personalized approach (similar to Dr. Eads' program).  These patients, with early Alzheimer's or Mild Cognitive Impairment, received targeted treatments based on their testing and achieved statistically significant improvement in multiple parameters of cognition. This report  paves the way for a larger trial of this precision medicine therapeutic approach.  Link to article here.

The published report in a peer-reviewed scientific journal of 255 patients treated with a highly personalized approach (ReCODE).  These participants, with early Alzheimer's, Mild Cognitive Impairment or Subjective Cognitive Impairment, each received targeted treatments with 74% of them showing improvement or stabilization of their cognition.  "...we observed that MoCA scores either significantly improved or stabilized in the entire participant pool..."  This report  validates this precision medicine therapeutic approach (similar to Dr. Eads' program).  Link to article here.

Dr. Bredesen's published report of 100 patients that were treated by several different physicians, each showing documented improvement in cognition. This report provides further documentation of the success of the protocol (now termed ReCODE) and the overall approach for those with Alzheimer's and its precursors.  Link to article here.

Provides details of ten individuals with MCI (mild cognitive impairment) or Alzheimer's disease, who, after individualized treatment addressing suboptimal metabolic parameters, resumed normal cognitive testing results.  This improvement was recognized by the patient and people closest to him/her. Link to article here.

The first description of the reversal of cognitive decline in people with early Alzheimer's disease or its precursors, MCI (mild cognitive impairment) and SCI (subjective cognitive impairment), was published in September 2014 by Dr. Bredesen. The multi-factorial and personalized therapeutic approach used  was dubbed metabolic enhancement for neurodegeneration (MEND).   "The magnitude of the improvement is unprecedented, providing additional objective evidence that this programmatic approach to cognitive decline is highly effective."  Link to article here.